DaVita Exceeds Q1 Earnings Expectations and Raises Full-Year Guidance
DaVita (NYSE:DVA) reported better-than-expected first-quarter 2026 results, driven by strong performance across treatment volume, revenue per treatment, and cost efficiency. The company raised its full-year guidance for adjusted operating income and earnings-per-share outlook. Integrated Kidney Care showed improvements in CMS's CKCC program with a notable increase in gross savings rates.
Tickers: $DVA